Scientist ousted from cancer study declines to testify to House panel.
D000288:Administrative Personnel; D001943:Breast Neoplasms; D026661:Clinical Trials Data Monitoring Committees; D005069:Evaluation Studies as Topic; D035082:Federal Government; D005260:Female; D005607:Fraud; D013502:General Surgery; D006076:Government; D033161:Government Regulation; D006805:Human Experimentation; D006801:Humans; D015337:Multicenter Studies as Topic; D009369:Neoplasms; D004364:Pharmaceutical Preparations; D012107:Research Design; D012108:Research Personnel; D015871:Scientific Misconduct; D012926:Social Control, Formal; D012927:Social Control, Informal; D012941:Social Responsibility; D013223:Statistics as Topic; D013629:Tamoxifen; D014481:United States; D018172:United States Office of Research Integrity; D014930:Women
Biomedical and Behavioral Research; National Cancer Institute; National Surgical Adjuvant Breast and Bowel Project; Office of Research Integrity; Popular Approach/Source; U.S. Congress; University of Pittsburgh